908 Devices (NASDAQ:MASS) Director Christopher Brown Sells 9,442 Shares

908 Devices Inc. (NASDAQ:MASS) Director Christopher Brown sold 9,442 shares of 908 Devices stock in a transaction on Monday, August 10th. The stock was sold at an average price of $9.03, for a total transaction of $85,261.26. Following the completion of the transaction, the director owned 813,917 shares in the company, valued at $7,349,670.51. This trade represents a 1.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

908 Devices Price Performance

MASS stock opened at $10.02 on Thursday. 908 Devices Inc. has a 52-week low of $5.03 and a 52-week high of $10.52. The company has a 50-day moving average of $8.26 and a two-hundred day moving average of $7.36. The stock has a market capitalization of $378.86 million, a price-to-earnings ratio of -10.55 and a beta of 0.66.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. 908 Devices had a negative return on equity of 12.29% and a negative net margin of 56.96%.The business had revenue of $16.07 million for the quarter, compared to analyst estimates of $15.37 million. Equities analysts expect that 908 Devices Inc. will post -0.4 EPS for the current fiscal year.

Key 908 Devices News

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. 908 Devices reported a loss of $0.11 per share, better than the $0.14 consensus loss, while revenue reached $16.07 million versus estimates of $15.37 million. Revenue increased 23% year over year, and the company said its adjusted EBITDA loss narrowed by more than half from the prior year. 908 Devices Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised the low end of its full-year outlook. 908 Devices now expects 2026 revenue of $68 million to $70 million, compared with the previous outlook’s lower starting point and roughly in line with the $68.6 million analyst consensus. The company’s guidance excludes potential AVCAD contribution from its core outlook, which may leave room for upside if that business contributes. 908 Devices Signals 2026 Revenue Outlook
• Positive Sentiment: Growth drivers remain intact. Demand for chemical-detection instruments from law enforcement, defense, and other mission-critical customers, along with recurring NIRLab revenue and upgrades such as VipIR, is supporting the bullish view. One analyst publication maintained a BUY rating after the earnings beat. 908 Devices Mission Critical Devices Drive Growth
• Neutral Sentiment: 908 Devices plans to present at the 17th Annual Midwest IDEAS Investor Conference, providing an opportunity for management to discuss its outlook and growth strategy. 908 Devices to Present at the Midwest IDEAS Investor Conference
• Negative Sentiment: Director Christopher D. Brown sold a combined 17,800 shares for approximately $162,000 across August 10 and 11. The sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their negative signaling value, and Brown still owns 805,559 shares after the transactions. 908 Devices SEC Insider Trading Filing

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a research note on Friday, August 7th. Roth Capital raised their price target on shares of 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. Stifel Nicolaus boosted their price objective on shares of 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Wall Street Zen cut shares of 908 Devices from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, 908 Devices presently has a consensus rating of “Hold” and an average target price of $12.50.

Institutional Trading of 908 Devices

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MASS. Allworth Financial LP acquired a new position in 908 Devices in the second quarter worth about $29,000. PCM Encore LLC acquired a new stake in 908 Devices during the second quarter valued at approximately $103,000. BlackRock Inc. bought a new stake in shares of 908 Devices in the 2nd quarter valued at approximately $16,915,000. Deutsche Bank AG acquired a new position in shares of 908 Devices in the 2nd quarter worth approximately $247,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of 908 Devices during the 2nd quarter worth approximately $962,000. Institutional investors own 88.06% of the company’s stock.

908 Devices Company Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.